Mucosal melanoma is rare and associated with extremely poor prognosis.No effective treatment for advanced mucosal melanoma patients.Investigators conducted a randomized phase II study in patients with previously untreated metastatic mucosal melanoma to characterize the efficacy and safety of bevacizumab when combined with carboplatin plus paclitaxel.
Description: Progression Free Survival is defined as the time from enrollment to the date of first documented disease progression or death from any cause.Measure: progress-free survival(PFS) Time: From randomization up to 144 weeks
Description: Any events,no matter related to interventions,occur during the period from the enrollment to death or 30 days after withdrawal from the trialMeasure: adverse event(AE) Time: From randomization up to144 weeks
Description: Overall survival was defined as the time from randomization to death from any cause.Measure: Overall Survival(OS) Time: Up to 144 weeks
There is one SNP
8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures Exclusion Criteria: 1. Mutations in C-KIT or BRAF-V600E, asked for other target treatments 2. Pregnant or lactation women 3. Acute infections without control. --- V600E ---